Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients

Thrombosis Research

Volumn 128, Issue 4, 2011, Pages

  Gale, Andrew J ^a   Elias, Darlene J ^a,b   Averell, Patricia M ^b   Teirstein, Paul S ^c   Buck, Mitchell ^a   Brown, Steven D ^a   Polonskaya, Zinaida ^a   Udit, Andrew K ^d   Finn, M G ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Division of Pulmonary and Critical Care Medicine   (United States)

^c SCRIPPS CLINIC   (United States)

^d OCCIDENTAL COLLEGE   (United States)

Author keywords

Anticoagulation; Bacteriophage Q ; Coronary intervention; Heparin; Protamine; Venous thrombosis

Indexed keywords

HEPARIN; HEPARIN ANTAGONIST; PROTAMINE SULFATE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; THROMBOSIS; VALIDATION STUDY; VIRUS LIKE AGENT;

AGED; AGED, 80 AND OVER; ALLOLEVIVIRUS; ANTICOAGULANTS; BLOOD COAGULATION; CAPSID PROTEINS; FEMALE; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTAMINES; TIME FACTORS; VIRION;

EID: 80054921482     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.03.021     Document Type: Article

References (32)

1. C. Peterson, C.W. Ham, and T. Vanderveen Improving heparin safety: A multidisciplinary invited conference Hosp Pharm 43 2008 491 497
2. D.C. Classen, L. Jaser, and D.S. Budnitz Adverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillance Jt Comm J Qual Patient Saf 36 2010 12 21
3. S. Schulman, and N.R. Bijsterveld Anticoagulants and their reversal Transfus Med Rev 21 2007 37 48 (Pubitemid 44881256)
4. M.A. Crowther, J.S. Ginsberg, D.M. Tollefsen, and M.A. Blinder Heparin R. Hoffman, E.J. Benz, S.J. Shattil, B. Furie, H.J. Cohen, L.E. Silberstein, Hematology Basic Principles and Practice 2000 Churchill Livingstone Philadelphia, PA 2046 2055
5. R.N. Pike, A.M. Buckle, B.F. Le Bonniec, and F.C. Church Control of the coagulation system by serpins. Getting by with a little help from glycosaminoglycans FEBS J 272 2005 4842 4851 (Pubitemid 41415108)
6. S.E. Kimmel, M.A. Sekeres, J.A. Berlin, L.R. Goldberg, and B.L. Strom Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting J Clin Epidemiol 51 1998 1 10 (Pubitemid 28026509)
7. J.C. Horrow Protamine: a review of its toxicity Anesth Analg 64 1985 348 361 (Pubitemid 15130775)
8. I.J. Welsby, M.F. Newman, B. Phillips-Bute, R.H. Messier, E.D. Kakkis, and M. Stafford-Smith Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgery Anesthesiology 102 2005 308 314 (Pubitemid 40189077)
9. S.E. Kimmel, M. Sekeres, J.A. Berlin, and N. Ellison Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass Anesth Analg 94 2002 1402 1408 (Pubitemid 34556613)
10. W. Jeske, C. Schroeder, M. Prechel, J.M. Walenga, and M. Bakhos Novel antagonists for low molecular weight heparin and heparin-like drugs Blood 114 2009
11. D.J. Cushing, W.D. Cooper, M.L. Cohen, J.R. McVoy, M. Sobel, and R.B. Harris Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist Eur J Pharmacol 635 2010 165 170
12. T. Mecca, G.M. Consoli, C. Geraci, S.R. La, and F. Cunsolo Polycationic calix[8]arenes able to recognize and neutralize heparin Org Biomol Chem 4 2006 3763 3768 (Pubitemid 44536088)
13. Y. Byun, V.K. Singh, and V.C. Yang Low molecular weight protamine: a potential nontoxic heparin antagonist Thromb Res 94 1999 53 61 (Pubitemid 29170400)
14. T.W. Wakefield, P.C. Andrews, S.K. Wrobleski, A.M. Kadell, S. Tejwani, and M.S. Hulin A [+ 18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation J Surg Res 63 1996 280 286 (Pubitemid 26197206)
15. A.K. Udit, C. Everett, A.J. Gale, K.J. Reiber, M. Ozkan, and M.G. Finn Heparin antagonism by polyvalent display of cationic motifs on virus-like particles Chembiochem 10 2009 503 510
16. E. Strable, D.E. Prasuhn Jr., A.K. Udit, S. Brown, A.J. Link, and J.T. Ngo Unnatural amino acid incorporation into virus-like particles Bioconjug Chem 19 2008 866 875 (Pubitemid 351614542)
17. A. Perkash A comparison of the quantitative action of protamine and heparin on blood coagulation. Significance in clinical and laboratory usage Am J Clin Pathol 73 1980 676 681 (Pubitemid 10047201)
18. F. Ni Ainle, R.J. Preston, P.V. Jenkins, H.J. Nel, J.A. Johnson, and O.P. Smith Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation Blood 114 2009 1658 1665
19. A.S. Brecher, and A.R. Roland Protamine inhibits formation of the covalent factor IXa-anti-thrombin complex Blood Coagul Fibrinolysis 19 2008 591 596
20. C. Kearon, S.R. Kahn, G. Agnelli, S. Goldhaber, G.E. Raskob, and A.J. Comerota Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 454S 545S (Pubitemid 351892971)
21. D.S. Weitz, and J.I. Weitz Update on heparin: what do we need to know? J Thromb Thrombolysis 29 2010 199 207
22. A. Vincentelli, B. Jude, and S. Belisle Antithrombotic therapy in cardiac surgery Can J Anaesth 53 2006 S89 S102
23. T.W. Wakefield, P.C. Andrews, S.K. Wrobleski, A.M. Kadell, A. Fazzalari, and B.J. Nichol Reversal of low-molecular-weight heparin anticoagulation by synthetic protamine analogues J Surg Res 56 1994 586 593 (Pubitemid 24222409)
24. A. DeLucia III, T.W. Wakefield, P.C. Andrews, B.J. Nichol, A.M. Kadell, and S.K. Wrobleski Efficacy and toxicity of differently charged polycationic protamine-like peptides for heparin anticoagulation reversal J Vasc Surg 18 1993 49 58
25. L.M. Lee, L.C. Chang, S. Wrobleski, T.W. Wakefield, and V.C. Yang Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model AAPS PharmSci 3 2001 E19
26. K.H. Teoh, E. Young, C.A. Bradley, and J. Hirsh Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass Circulation 88 1993 II420 II425
27. D.E. Prasuhn Jr., P. Singh, E. Strable, S. Brown, M. Manchester, and M.G. Finn Plasma clearance of bacteriophage Qbeta particles as a function of surface charge J Am Chem Soc 130 2008 1328 1334 (Pubitemid 351171012)
28. J. Butterworth, Y.A. Lin, R. Prielipp, J. Bennett, and R. James The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers Anesth Analg 94 2002 514 522 (Pubitemid 34177542)
29. P. Singh, D. Prasuhn, R.M. Yeh, G. Destito, C.S. Rae, and K. Osborn Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo J Control Release 120 2007 41 50 (Pubitemid 46876741)
30. A.C. Tissot, P. Maurer, J. Nussberger, R. Sabat, T. Pfister, and S. Ignatenko Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study Lancet 371 2008 821 827 (Pubitemid 351323893)
31. P. Maurer, G.T. Jennings, J. Willers, F. Rohner, Y. Lindman, and K. Roubicek A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity Eur J Immunol 35 2005 2031 2040 (Pubitemid 41015042)
32. E. Strable, and M.G. Finn Chemical modification of viruses and virus-like particles Curr Top Microbiol Immunol 327 2009 1 21